Sign up for the Abwiz Bio Newsletter to get actionable advice and exclusive deals direct to your inbox.
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (A11) rabbit mAb FITC conjugate
Customers Also Viewed
|Description||Human Erk1 and Erk2 Ser/Thr kinases share 84% sequence identity and nearly all functions. These MAP kinases are activated in response to mitogens and growth factors as part of the Ras-Raf-MEK-ERK signal transduction cascade. This pathway regulates cell survival, differentiation, adhesion, cell cycle progression, and many other cellular processes. Upon phosphorylation, Erk1/2 translocate to the nucleus to activate transcription factors including c-Fos, Elk1, Ets1, and SP-1. There are more than 175 known cytoplasmic and nuclear substrates of Erk1/2. The Erk1/2 cascade is upregulated in many human cancers, even when oncogenic mutations are not found. Multiple small-molecule inhibitors of Erk1/2 have been developed, including ones targeting the ATP-binding site either competitively or irreversibly.|
|Validated Reactivity||Human, Mouse|
|Cross Reactivity||Predicted to work with mouse, rat, and other homologues.|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Thr202/Tyr204 of human phospho Erk1/2.|
|Formulation||1X PBS, 0.09% NaN3, 0.2% BSA|
|Recommended Usage||For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application.|
|Pseudonyms||Mitogen-activated protein kinase 3, MAPK3, ERT2, p44-MAPK, PRKM3, Mitogen-activated protein kinase 1, MAPK1, ERT1, p42-MAPK, PRKM1, PRKM2|
|References||Roskoski Jr R. (2012) Pharmacological Research. 66: 105-143.|
Flow cytometric analysis of Jurkat cells secondary antibody only negative control (blue) or treated with U0126 (red) or treated with TPA (green) using Phospho-ERK1/2 (Thr202/Tyr204) A11 FITC antibody ERK12T202Y204-A11. Cat. #1113.